Epidemiology of non-squamous non-small cell lung cancer in New Zealand: A focus on EGFR gene mutation
type: CreativeWork
description: Background: Lung cancer is one of the major health burdens with persistent high incidence and poor survival. Treatment with Tyrosine Kinase Inhibitors (TKIs) that target Epidermal Growth Factor Receptor (EGFR) significantly improves disease outcomes for non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with EGFR mutation. A better understanding is needed of the epidemiology of lung cancer in relation to EGFR mutation and strategies to facilitate identification of EGFR mutation-positive patients who may be eligible for EGFR targeted treatment. Thus, this PhD research aimed to contribute knowledge to this area of research by 1) estimating the incidence of EGFR mutation-specific non-squamous NSCLC, 2) investigating factors associated with survival of EGFR mutation-specific non-squamous NSCLC, and 3) estimating the probabilities of EGFR mutation positivity for individual patients using a predictive model to assist in treatment decision-making where tissue biopsy results were unavailable. Methods: Data sources: This research was based on all patients who were diagnosed with non-squamous non-small cell lung cancer (NSCLC) in northern New Zealand between 1 February 2010 and 31 July 2017 (n=3815). The patients were identified and their demographic and clinico-pathological information was collected from the population-based New Zealand Cancer Registry (NZCR). The NZCR data were then linked with TestSafe clinical information sharing database, laboratory reports, individual patient medical records, pharmaceutical records and mortality records to obtain EGFR mutation test results, further clinical, pathological and treatment information. Statistical analysis: 1) The incidence rates were calculated for EGFR mutation-positive and negative non-squamous NSCLC, in subgroups of patients by age, sex, ethnicity, and smoking status. The incidence rates were age-standardised using the WHO standard population, and were also estimated taking into account incomplete EGFR mutation tes…
abstract: Background: Lung cancer is one of the major health burdens with persistent high incidence and poor survival. Treatment with Tyrosine Kinase Inhibitors (TKIs) that target Epidermal Growth Factor Receptor (EGFR) significantly improves disease outcomes for non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with EGFR mutation. A better understanding is needed of the epidemiology of lung cancer in relation to EGFR mutation and strategies to facilitate identification of EGFR mutation-positive patients who may be eligible for EGFR targeted treatment. Thus, this PhD research aimed to contribute knowledge to this area of research by 1) estimating the incidence of EGFR mutation-specific non-squamous NSCLC, 2) investigating factors associated with survival of EGFR mutation-specific non-squamous NSCLC, and 3) estimating the probabilities of EGFR mutation positivity for individual patients using a predictive model to assist in treatment decision-making where tissue biopsy results were unavailable. Methods: Data sources: This research was based on all patients who were diagnosed with non-squamous non-small cell lung cancer (NSCLC) in northern New Zealand between 1 February 2010 and 31 July 2017 (n=3815). The patients were identified and their demographic and clinico-pathological information was collected from the population-based New Zealand Cancer Registry (NZCR). The NZCR data were then linked with TestSafe clinical information sharing database, laboratory reports, individual patient medical records, pharmaceutical records and mortality records to obtain EGFR mutation test results, further clinical, pathological and treatment information. Statistical analysis: 1) The incidence rates were calculated for EGFR mutation-positive and negative non-squamous NSCLC, in subgroups of patients by age, sex, ethnicity, and smoking status. The incidence rates were age-standardised using the WHO standard population, and were also estimated taking into account incomplete EGFR mutation tes…
author: Aye, Phyu Sin
license: https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
date published: 2021
date modified: 2026-07-24T01:03:37Z
provider: University of Auckland
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: ResearchSpace@Auckland

PropertyValue
property ID: Handle
value: https://hdl.handle.net/2292/55277